Cytochrome P450 substrate specificities, substrate structural templates and enzyme active site geometries

Drug Metabolism and Drug Interactions

Volumn 15, Issue 1, 1999, Pages 1-49

  Lewis, David F V ^a   Dickins, Maurice ^b   Eddershaw, Peter J ^b   Tarbit, Mike H ^b   Goldfarb, Peter S ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 NITROPHENOL; 7 ETHOXY 4 TRIFLUOROMETHYLCOUMARIN; CAFFEINE; COUMARIN; COUMARIN DERIVATIVE; CYTOCHROME P450 ISOENZYME; DEBRISOQUINE; DIMETHYLNITROSAMINE DEMETHYLASE; ESTRADIOL; ETHOXYRESORUFIN; NIFEDIPINE; OMEPRAZOLE; PHENACETIN O DEETHYLASE; TOLBUTAMIDE; UNCLASSIFIED DRUG; XENOBIOTIC AGENT;

BINDING AFFINITY; DRUG METABOLISM; ENZYME ACTIVE SITE; ENZYME SPECIFICITY; ENZYME SUBSTRATE; GEOMETRY; HUMAN; REVIEW;

EID: 0032985950     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/dmdi.1999.15.1.1     Document Type: Review

References (110)

1. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6: 1-42.
2. Bachmann KA. The cytochrome P450 enzymes of hepatic drug metabolism; how are their activities assessed in vivo, and what is their clinical relevance? Am J Therapeut 1996; 3: 150-171.
3. Smith DA, Ackland MJ, Jones BC. Properties of cytochrome P450 isoenzymes and their substrates Part 1: active site characteristics. Drug Discovery Today 1997; 2: 406-414.
4. Smith DA, Ackland MJ, Jones BC. Properties of cytochrome P450 isoenzymes and their substrates Part 2. properties of cytochrome P450 substrates. Drug Discovery Today 1997; 2: 479-486.
5. Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes; a status report summarizing their reactions, substrates, inducers and inhibitors. Drug Metab Rev 1997; 29: 413-580.
6. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997; 32; 210-258.
7. Smith DA, Jones BC. Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes, Biochem Pharmacol 1992; 44: 2089-2098,
8. Smith DA. Species differences in metabolism and pharmacokinetics: are we close to an understanding? Drug Metab Rev 1991; 23: 355-373.
9. Korzekwa KR, Jones JP. Predicting the cytochrome P450 mediated metabolism of xenobiotics. Pharmacogenetics 1993; 3- 1-18.
10. Negishi M, Iwasaki M, Juvonen RO, Sueyoshi T, Darden TA, Pederson LG. Structural flexibility and functional versatility of cytochrome P450 and rapid evolution. Mutat Res 1996; 350: 43-50.
11. Lewis DFV, Lake BG. Molecular modelling of members of the P4502A subfamily: application to studies of enzyme specificity. Xenobiotica 1995; 25: 585-598.
12. Soucek P, Gut I. Cytochromes P450 in rats: structures, functions, properties and relevant human forms. Xenobiotica 1992; 22: 83-103.
13. Nedelcheva V, Gut I. P450 in the rat and man: methods of investigation, substrate specificities and relevance to cancer. Xenobiotica 1994; 24: 1151-1175.
14. Gonzalez FJ, Gelboin, HV. Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab Rev 1994; 26: 165-183.
15. Avdeef A. Assessment of distribution-pH profiles. In: Pliska V, Testa B, van de Waterbeemd H, eds. Lipophilicity in Drug Action and Toxicology. Weinheim: VCH, 1996; 109-139.
16. Csizmadia F, Tsantili-Kakoulidou A, Panderi I, Darvas F. Prediction of distribution coefficient from structure 1 Estimation method. J Pharm Sci 1997; 86: 865-871.
17. van de Waterbeemd H, Mannhold R. Lipophilicity descriptors for structure-property correlation studies: overview of experimental and theoretical methods and a benchmark of log P calculations. In: Pliska V, Testa B, van de Waterbeemd H, eds. Lipophilicity in Drug Action and Toxicology. Weinheim: VCH, 1996; 401-418.
18. Strobl GR, von Kruendener S, Stockigt J, Guengerich FP, Wolff T. Development of a pharmacophore for inhibition of human liver cytochrome P450 2D6: molecular modelling and inhibition studies. J Med Chem 1993; 36: 1136-1145.
19. Lewis DFV, Eddershaw PJ, Goldfarb PS, Tarbit MH. Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102; structural studies on specific CYP2D6 substrate metabolism. Xenobiotica 1997:27:319-340.
20. Lewis DFV, Dickins M, Weaver RL, Eddershaw PJ, Goldfarb PS, Tarbit MH. Molecular modelling of human CYP2C subfamily enzymes CYP2C9 and CYP2C19: rationalization of substrate specificity and site-directed mutagenesis experiments in the CYP2C subfamily. Xenobiotica 1998; 28: 235-268.
21. Lewis DFV, Eddershaw PJ, Goldfarb PS, Tarbit MH. Molecular modelling of CYP3A4 from an alignment with CYP102: identification of key interactions between putative active site residues and CYP3A-specific chemicals. Xenobiotica 1996; 26: 1067-1086.
22. Lewis DFV, Bird MG, Parke DV. Molecular modelling of CYP2E1 enzymes from rat, mouse and man: an explanation for species differences in butadiene metabolism and potential carcinogenicity, and rationalization of CYP2E substrate specificity. Toxicology 1997; 118: 93-113.
23. Lewis DFV, Lake BG. Molecular modelling of CYP1A subfamily members based on an alignment with CYP102: rationalization of CYP1A substrate specificity in terms of active site amino acid residues. Xenobiotica 1996; 26: 723-753.
24. Goldstein JA, de Morais SMF. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994; 4: 285-299.
25. Lewis DFV. Cytochromes P450: Structure, Function and Mechanism. London. Taylor & Francis, 1996.
26. BM-3 and other inducible bacterial P450 cytochromes: biochemistry and regulation Ann Rev Pharmacol Toxicol 1991; 31: 177-203.
27. BM-3, a prototype for microsomal P450s. Science 1993; 261: 731-736
28. Ellis SW, Rowland K, Ackland MJ, Rekka E, Simula AP, Lennard MS, Wilf CR, Tucker GT. Influence of amino acid 374 of cytochrome P-4502D6 (CYP2D6) on the regio- and enantio-selective metabolism of metoprolol. Biochem J 1996; 316: 647-654.
29. Modi S, Gilham DE, Sutcliffe MJ, Lian L-Y, Primrose WU, Wolf CR, Roberts GCK. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine as a substrate of cytochrome P450 2D6: allosteric effects of NADPH-cytochrome P450 reductase. Biochemistry 1997; 36: 4461-4470.
30. Szklarz GD, He Y-Q, Kedzie KM, Halpert JR, Burnett, VL. Elucidation of amino acid residues critical for unique activities of rabbit cytochrome P450 2B5 using hybrid enzymes and reciprocal site-directed mutagenesis with rabbit P4502B4. Arch Biochem Biophys 1996; 327: 308-313.
31. de Groot MJ, Vermeulen NPE, Kramer JD, Van Acker FAA, Donné-Opden Kelder GM. A three-dimensional model for human cytochrome P450 2D6 based on the crystal structures of P450101, P450102 and P450108. Chem Res Toxicol 1996; 9: 1079-1091.
32. Lewis DFV, Lake BG, Parke DV. Molecular orbital-generated QSARs in an homologous series of alkoxyresorufins and studies of their interactive docking with cytochromes P450. Xenobiotica 1995; 25: 1355-1369.
33. Lewis DFV, Lake BG. Molecular modelling of human CYP2B isoforms and their interaction with substrates, inhibitors and redox components. Xenobiotica 1997; 27: 443-487.
34. Lewis DFV. The CYP2 family: models, mutants and interactions. Xenobiotica 1998; 28: 617-661.
35. Lewis DFV, Lake BG. Molecular modelling and quantitative structure-activity (QSAR) studies on the interaction of omeprazole with cytochrome P450 enzymes. Toxiclogy 1998; 125: 31-44.
36. BM-3 haem domain complexed with the fatty acid substrate, palmitoleic acid. Nature Struct Biol 1997; 4: 140-145.
37. Modi S, Sutcliffe MJ, Primrose WH, Lian L-Y, Roberts GCK. The catalytic mechanism of cytochrome P450 BM3 involves a 6Å movement of the bound substrate on reduction Nature Struct Biol 1996; 3: 414-417.
38. cam ternary complex. Biochemistry 1989; 28: 7586-7592.
39. cam X-ray structure. Meth Enzymol 1991, 206: 11-30.
40. Lake BG, Lewis DFV. The CYP4 family. In: Ioannides C, ed. Cytochromes P450 - Metabolic and Toxicological Aspects. Boca Raton, FL: CRC Press, 1996; 271-297.
41. Sesardic D, Boobis AR, Murray BP, Murray S, Segura J, de la Torre R, Davies DS. Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br J Clin Pharmacol 1990; 29: 651-663.
42. Kunze KL, Trager WF. Isoform selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem Res Toxicol 1993; 6: 649-656.
43. coh substrate specificity by mutation of a single amino-acid residue. Nature 1989; 339: 632-634.
44. Nims RW, Lubet RA. The CYP2B subfamily, In: Ioannides C, ed. Cytochrome P450 - Metabolic and Toxicological Aspects. Boca Raton, FL: CRC Press, 1996; 135-160.
45. Heyn H, White RB, Stevens, JC. Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin. Drug Metab Disposition 1996; 24: 948-954.
46. He Y, Luo Z, Klekotka PA, Burnett VL, Halpert JR. Structural determinants of cytochrome 2B1 specificity: evidence of five substrate recognition sites. Biochemistry 1994; 33: 4419-4424
47. Hasler JA, Harlow GR, Szklarz GD, John GM, Kedzie KM, Burnett VL, He Y-A, Kaminsky LS, Halpert JR. Site-directed mutagenesis of putative substrate recognition sites in cytochrome 2B1: importance of amino acid residues 114, 290 and 363 for substrate specificity. Mol Pharmacol 1994; 46: 338-345.
48. Szklarz GD, He Y-A, Halpert JR. Site-directed mutagenesis as a tool for molecular modelling of cytochrome P4502B1. Biochemistry 1995; 34: 14312-14322.
49. Miners JO, Birkett DJ. Use of tolbutamide as a substrate probe for human hepatic P4502C9. Meth Enzymol 1996; 272: 139-145.
50. Polic-Scaife S, Attias R, Dansette PM, Mansuy D. The substrate binding site of human liver cytochrome P4502C9: An NMR study. Biochemistry 1997; 36: 12672-12682.
51. Ibeanu GC, Ghanayem BI, Linko P, Li L, Pedersen LG, Goldstein JA. Identification of residues 99, 220 and 221 of human cytochrome P4502C19 as key determinants of omeprazole hydroxylase activity. J Biol Chem 1996; 271: 12496-12501.
52. Mancy A, Broto P, Dijols S, Dansette PM, Mansuy D. The substrate binding site of human liver cytochrome P4502C9: An approach using designed tienilic acid derivatives and molecular modelling. Biochemistry 1995; 34: 10365-10375.
53. von Wachenfeldt C, Johnson EF. Structures of eukaryotic cytochrome P450 enzymes, In: Ortiz de Montellano PR, ed. Cytochrome P450. New York: Plenum, 1995; 183-223.
54. Hsu M-H, Griffin KJ, Wang Y, Kemper B, Johnson EF A single amino acid substitution confers progesterone 6β-hydroxylase activity to rabbit cytochrome P4502C3. J Biol Chem 1993; 268: 6939-6944.
55. Richardson TH, Johnson EF. Alterations of the regiospecificity of progesterone metabolism by the mutagenesis of two key amino acid residues in rabbit cytochrome P4502C3V. J Biol Chem 1994; 269: 23927-23943.
56. Kronbach T, Kemper B, Johnson, EF. A hypervariable region of P450IIC5 confers progesterone 21-hydroxylase activity to P450IIC1. Biochemistry 1991; 30: 6097-6102.
57. Straub P, Johnson EF, Kemper B. Hydrophobic side chain requirements for lauric acid and progesterone hydroxylation at amino acid 113 in cytochrome P4502C2, a potential determinant of substrate specificity. Arch Biochem Biophys 1993; 306: 521-527.
58. Ellis SW, Hayhurst GP, Smith G, Lightfoot T, Wang MMS, Simula AP, Ackland MJ, Sternberg MJE, Lennard MS, Tucker GT, Wolf CR. Evidence that aspartic acid 301 is a critical substrate-contact residue in the active site of cytochrome P4502D6. J Biol Chem 1995; 270 29055-29058.
59. Hayhurst GP. Analysis of the structure-function relationships of P4502D6 by site-directed mutagenesis. Ph.D. Thesis, 1997; University of Sheffield, UK.
60. Koop DR, Laethem CL, Tierney DJ. The utility of p-nitrophenol hydroxylation in P450IIE1 analysis. Drug Metab Rev 1989; 20: 541-551.
61. Tassaneeyakul W, Veronese ME, Birkett DJ, Gonzalez FJ, Miners JO. Validation of 4-nitrophenol as an in vitro substrate probe for human liver CYP2E1 using cDNA expression and microsomal kinetic techniques. Biochem Pharmacol 1993; 46: 1975-1981
62. Hargreaves MB, Jones BC, Smith DA, Gerscher A. Inhibition of p-nitrophenol hydroxylase in rat liver microsomes by small aromatic and heterocyclic molecules. Drug Metab Disposition 1994, 22 806-810.
63. Fukuda T, Imai Y, Komon M, Nakamura M, Kusunose E, Satouchi K, Kusunose M Replacement of Thr-303 of P4502E1 with serine modifies the regioselectivity of its fatty acid hydroxylase activity. J Biochem 1993; 113: 7-12
64. Gotoh O. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem 1992; 267: 83-90.
65. Li AP, Kaminski DL, Rasmussen A. Substrates of human hepatic cytochrome P4503A4. Toxicology 1995; 104: 1-8.
66. Ueng Y-F, Kuwabara T, Chun Y-J, Guengerich FP. Cooperativity in oxidations catalyzed by cytochrome P4503A4 Biochemistry 1997; 36: 370-381.
67. Harlow GR, Halpert JR. Alanine-scanning mutagenesis of a putative substrate recognition site in human cytochrome P4503A4. J Biol Chem 1997; 272: 5396-5402.
68. Simon Z, Motoc I, Chiriac A, Molecular basis of receptor ligand interactions. In: Voiculetz N, Motoc I ,Simon Z, eds. Specific Interactions and Biological Recognition Processes. Boca Raton, FL: CRC Press, 1993; 17-79.
69. Sharp KA, Nicholls A, Fine RF, Honig B. Reconciling the magnitude of the microscopic and macroscopic hydrophobic effects. Science 1991; 252: 106-109.
70. Williams DH, Searle MS, MacKay JP, Gerhard U, Maplestone RA. Toward an estimation of binding constants in aqueous solution: studies of associations of vancomycin group antibiotics. Proc Natl Acad Sci USA 1983; 90: 1172-1178.
71. Lewis DFV, Eddershaw PJ, Dickins M, Tarbit MH, Goldfarb PS. Structural determinants of cytochrome P450 substrate specificity, binding affinity and catalytic rate. Chem-Biol Inter 1998; 30: 709-737.
72. Lewis DFV, Pratt M. The P450 catalytic cycle and oxygenation mechanism. Drug Metab Rev 1998; 30: 739-786.
73. Sugar SG, Cinti DL, Gibson GG, Schenkman JB. Spin state control of the hepatic cytochrome P450 redox potential. Biochem Biophys Res Comm 1979; 90: 925-932
74. Sugar SG, Gunsalus IC. A thermodynamic model of regulation: modulation of redox equilibria in camphor monooxygenase. Proc Natl Acad Sci USA 1976; 73: 1078-108.
75. Sligar SG, Gunsalus IC. Proton coupling in the cytochrome P450 spin and redox equilibria. Biochemistry 1979; 18: 2290-2295.
76. Sligar SG. Coupling of spin, substrate and redox equilibria in cytochrome P450. Biochemistry 1976; 15: 5399-5406.
77. Blanck J, Rein H, Sommer M, Ristau O, Smettan G, Ruckpaul K. Correlations between spin equilibrium shift, reduction rate and N-demethylation activity in liver microsomal cytochrome P450 and a series of benzphetamine analogues as substrates. Biochem Pharmacol 1983; 32: 1683-1688.
78. Schwarze W, Blanck J, Ristau O, Jamg GR, Pommerening K, Rein H, Ruckpaul K. Spin state control of cytochrome P-450 reduction and catalytic activity in a reconstituted P-450 LM2 system as induced by a series of benzphetamine analogues. Chem-Biol Inter 1985; 54: 127-141.
79. Petzold DR, Rein H, Schwarz D, Sommer S, Ruckpaul K. Relation between the structure of benzphetamine analogues and their binding properties to cytochrome P450LM2. Biochim Biophys Acta 1985; 829: 253-261.
80. Archakov AI, Bachmanova GI. Cytochrome P-450 and Active Oxygen. London: Taylor & Francis, 1990.
81. Imai Y, Sato R, Iyanagi, T. Rate-limiting step in the reconstituted microsomal drug hydroxylase system. J Biochem 1997, 82: 1237-1246.
82. Guengerich FP. Oxidation-reduction properties of rat liver cytochromes P450 and NADPH-cytochrome P450 reductase related to catalysis in reconstituted systems. Biochemistry 1983; 22: 2811-2820.
83. Hasemann CA, Kurumbail RG, Boddupalli SS, Peterson JA, Deisenhofer J. Structure and function of cytochromes P450: a comparative analysis of three crystal structures. Structure 1995; 3: 41-62.
84. Stellwagen E. Haem exposure as the determinate of oxidation-reduction potential haem proteins. Nature 1978; 275: 73-74.
85. Lewis DFV, Ioannides C, Parke DV. A quantitative structure-activity relationship study on a series of 10 para-substituted toluenes binding to P4502B4 (CYP2B4) and also their hydroxylation rates. Biochem Pharmacol 1995; 50: 619-625.
86. Roffey SJ. Structure-activity relationships in the metabolism of a series of tertiary amines by cytochrome P450. Ph.D. Thesis, 1993: University of Surrey, Guildford, Surrey, UK.
87. 12- Chem Comm 1973; 810-812.
88. Addison AW, Burman S. Ligand-dependent redox chemistry of Glycera dibranchiata hemoglobin. Biochim Biophys Acta 1985; 828: 362-368.
89. Hawkins BK, Dawson JH. Oxygen activation by heme-containing monoxygenases: cytochrome P450 and secondary amino mono-oxygenase. Active site structures and mechanisms of action. Front Biotransform 1992; 7: 216-278.
90. Blanck J, Ristau O, Zhukov AA, Archakov AI, Rein H, Ruckpaul K. Cytochrome P450 spin state and leakiness of the mono oxygenase pathway. Xenobiotica 1991; 21- 121-135.
91. Watanabe Y, Iyanagi T, Oae S. One electron transfer mechanism Ln the enzymatic oxygenation of sulfoxide to sulfone promoted by a reconstituted system with purified cytochrome P450. Tetrahedron Lett 1982; 23: 533-536.
92. IN-dimthylanilines by cytochrome P450: estimation of the effective oxidation-reduction potential of cytochrome P450. Biochemistry 1989; 28: 2071-2077.
93. Guengerich FP, MacDonald TL, Chemical mechanisms of catalysis by cytochromes P450: a unified view. Accounts Chem Res 1984; 17: 9-16.
94. Cnubben NHP, Vervoort J, Veeger C, Rietjens IMCM Study of the regioselectivity and mechanism of the aromatic hydroxylation of monofluoroanilines. Chem-Biol Inter 1992; 85: 151-172.
95. Tyrakowska B, Cnubben NHP, Soffers AEMF, Wobbes T, Rietiens IMCM. Comparative MO-QSAR studies in various species including man. Chem-Biol Inter 1996; 100: 187-201.
96. Yin H, Anders MW, Korzekwa KR, Higgins L, Thummel KE, Kharasch ED, Jones JP Designing safer chemicals' predicting the rates of metabolism of halogenated alkanes. Proc Natl Acad Sci USA 1995; 92: 11076-11080.
97. Traylor TG, Xu F. Model reactions related to cytochrome P450 Effects of alkene structure on the rates of epoxide formation. J Am Chem Soc 1998; 110: 1953-1958.
98. 3 radical reactivity in the troposphere. Atmos Environ 1990; 24A: 73-78.
99. Plant AL, Pownall HJ, Smith LC. Transfer of polycyclic aromatic hydrocarbons between model membranes: relation to carcinogenicity Chem-Biol Inter 1983; 44: 237-246.
100. Smith DA. Physicochemical properties in drug metabolism and pharmacokinetics. In: van de Waterbeemd H, Testa B, Folkers G, eds. Computer-Assisted Lead Finding and Optimization. New York: Wiley, 1997; 267-276.
101. Guengerich FP. Human cytochrome P450 enzymes. In: Ortiz de Montellano PR. ed. Cytochrome P450. New York: Plenum, 1995; 473-535.
102. Vermeulen NPE. Role of metabolism in chemical toxicity. In: Ioannides C, ed. Cytochromes P450 - Metabolic and Toxicological Aspects. Boca Raton, FL: CRC Press, 1996; 29-53.
103. Honkakoshi P, Negishi M. The structure, function and regulation of cytochrome P4502A enzymes. Drug Metab Rev 1997; 29: 977-996.
104. Koymans L, Vermeulen NPE, Van Acker SABE, te Koppele JM, Heykants JJP, Lavrijsch K, Meuldermans W, Donné-op den Kelder GM. A predictive model for substrates of cytochrome P450-debrisoquine (2D6). Chem Res Toxicol 1992; 5: 211-219.
105. Daly AK, Brockmoller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang J-D, Idle JR, Ingelman-Sundberg M, Ishizaki T, Jacqz-Aigrain E, Meyer UA, Nebert DW, Steen VM, Wolf CR, Zanger VM. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996; 6: 193-201.
106. Tassaneeyakul W, Mohamed Z, Birkett DJ, McManus ME, Veronese ME, Tukey RH, Quattrochi LC, Gonzalez FJ, Miners JO. Caffeine as a probe for human cytochromes P450: validation using cDNA-expression. immunoinhibition and microsomal kinetic and inhibitor techniques. Pharmacogenetics 1992; 2: 173-183.
107. Lewis DFV, Ioannides C, Parke DV. An improved and updated version of the COMPACT procedure for the valuation of P450-mediated chemical activation. Drug Metab Rev 1998; 30: 709-737.
108. Houston JB, Carlile DJ Prediction of hepatic clearance from microsomes, hepatocytes and liver slices. Drug Metab Rev 1997; 29: 891-922.
109. Lewis DFV, Moereels H, Lake BG, Ioannides C, Parke DV Molecular modelling of enzymes and receptors involved in carcinogenesis: QSARs and COMPACT-3D. Drug Metab Rev 1994; 26: 261-285.
110. Lewis DFV. COMPACT and the importance of frontier orbitals in toxicity mediated by the cytochrome P450 mono-oxygenase system. Toxicol Modelling 1995; 1: 85-97.